Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep Enjoy the weekend everyone. Next week will be 4 days of fun
Shares are sparse. They are trying to break some free. They are not getting mine for a while. Plenty of time. Tic tock
Yes. I believe the trades pre-premarket were mm’s fighting for shares. I saw it as high as 12.39
Such strength here. Hold tight and make them pay. There really aren’t many shares available. If they want in that bad they will pay up. Those would be some crazy numbers. Life changing.
Getting the Novavax trajectory should be good prepared, everythings has a technical limits. After eruption may be established 3-6 month Sleep and bigger eruption want to follow, three times RSI 30-90-30 and we are at $390. How the VANGA said: "Cancer is going to chain down (with Versamune etc) at the beginning of 21. century."
There’s plenty of praise for everyone. Unfortunately I couldn’t go back far enough. But thank you. Where do you see it going now?
Just for my BIG SMILE, I WAS THE FIRST !!!
Go to the history and You will find a prove my words.
We were thinking about that. Shares.
Shhhh let shorty pay up. Someone wants shares in a bad way. Not to many available even at this price.
Gotcha yea just noticed.
Look at his sticky post up top. Gives you a good idea of his beliefs.
No one knows. Hope he is ok.
What happened to Fress ?
Gotcha
When Fress was around he thought well over 20 and even more with the right news. This is in beast mode.
Ugh yea I thought for sure this would slow down lol how high can this go seriously?
Shorts screwed.
Lol that would be nice
FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Company’s proprietary Versamune® T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership. This collaboration seeks to raise awareness of new and developing treatment options, including available clinical trials, for patients with HPV-attributed head and neck cancer diagnoses.
Strategic partnership offers both organizations a way to share information about emerging treatment options with clinicians and patients battling HPV-attributed head and neck cancer
https://finance.yahoo.com/news/pds-biotechnology-establishes-partnership-head-113000402.html
lol, someone posted on the yahoo board that everyone is selling their OCGN to get on board with PDS
I resemble that remark.
"I haven’t sold one share of my position which is probably foolish but to many extraordinary things ahead."
It is my #1 investment, now by a significant margin, and I only began investing in it last August. I exercised some options last week at $7.50 and I plan on selling those shares by next Friday, just to be safe. I had no intention of buying those shares, I just couldn't sell the underlying option with what I think I see. I figured I would make far more by exercising the expiring option at $7.50 then selling the stock later. I thought I would sell Monday but I am greedy and decided to hold, glad I did.
After I sell those shares, my next sale will be at $20 to get my investment out then let the rest ride, hopefully to triple digits within a year or so. Depending on the presentation in a week and a half, this could go parobolic. So little institutional ownership, <15% as of 03/31/21, which will cause an explosion after the Oral presentation if the data are as good as preliminary. I can't imagine the data will be worse and I think it will only be better. Unreal how high I think this could go with the right following in a short time frame.
Too bad Fress isn't around. Hope he is OK.
I sold some but I’m playing with almost al house money and don’t plan on selling anytime soon.
Still grossly undervalued at this price btw. I haven’t sold one share of my position which is probably foolish but to many extraordinary things ahead.
Great Day here. Great job to all longs. So much potential here to go higher with some updates or a buyout.
Owe all of you. Any other plays soon?
My only other one coming soon I mentioned. Always looking for others !
yes, I really owe him for this play :)
Truly a beast.
Jeez look at it go
Wish I owned more!
Good call over here officially up over 100 percent !
Think so. :). Tons of strength here into ASCO.
Is $10. Gonna be a thing today
Too bad Fress not around to enjoy his fruits. Good call.
Take a look at SLS. Sounds like the will be getting some data out soon!
Jeez this thing just keeps going lol
Yeah Man! Weeee!
I think the $8.80 just got crushed.
Very interesting but why would they get AA or breakthrough designation when Bintrafusp alfa in HPV positive patients did not receive one of those (yet)?
Bintrafusp alfa is now in phase 2 trial (open label single arm 146 patients) and results will probably be published in 1Q2022.
As for previous results - The median overall survival among the 43 patients was 16.2 months. This “compares very favorably” to the survival of 9 to 11 months seen in patients with HPV-related cancers in previous trials testing immune checkpoint inhibitors that target PD-1 or PD-L1, noted Julius Strauss, M.D., of NCI’s Center for Cancer Research (CCR), who presented the results of the trial in Atlanta.
https://www.cancer.gov/news-events/cancer-currents-blog/2019/immunotherapy-y-trap-hpv-cancershttps://www.cancer.gov/news-events/cancer-currents-blog/2019/immunotherapy-y-trap-hpv-cancers
Followers
|
49
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1582
|
Created
|
06/17/20
|
Type
|
Free
|
Moderators |
https://pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf ![]() |
DEVELOPING POWERFUL, SAFE, VERSATILE IMMUNOTHERAPIES |
![]() ![]() |
PDSB Versamune® T cell Platform. Our Versamune® platform trains the immune system to unleash a powerful targeted T-cell attack and could dramatically improve treatment and patient outcomes across the cancer spectrum. |
PDSB analyst coverage: |
SECOND GENERATION COVID-19 VACCINE PHASE 3 Q4 2021 PDSB $100.00 PRICE PER SHARE =2.2 BILLION MARKET CAP |
PDSB biz presentation 2021: PDSB White Paper: https://pdsbiotech.com/images/pdf/presentation/2021/Whitepaper-2021_v6.pdf PDSB Biotech preparing to initiate 3 CANCER Phase 2 clinical studies for lead candidate PDS0101: https://www.youtube.com/watch?v=iYZRmRmRtUI&t=2s OPPENHEIMER Annual Healthcare Conference MARCH 16TH 2021 https://wsw.com/webcast/oppenheimer9/register.aspx?conf=oppenheimer9&page=pdsb&url=https://wsw.com/webcast/oppenheimer9/pdsb/2708189 PDSB website: |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |